ACTC

[大白呼]

英国《金融时报》克莱夫•库克森(Clive Cookson)伦敦报道

　　美国科学家在不损伤胚胎的情况下，成功创造出了人类胚胎干细胞。目前批评者出于基本的伦理原因反对干细胞研究，但上述新发现似乎成功避开了这一反对理由。

　　《自然》(Nature)科学杂志今天在网上公布了这一突破，它可能有助于该领域吸引更多公共资金，并增加该研究对商业投资的吸引力。

　　美国生物科技集团先进细胞技术公司(Advanced Cell Technology)的研究员，通过从刚受精的胚胎中采集个体细胞，生成了干细胞培养组织，而胚胎则未受损坏。到目前为止，干细胞生成都需要从稍成熟的胚胎中采集较大数量的细胞，从而使胚胎不可避免地受到损伤。

　　达特茅斯学院(Dartmouth College)伦理学院主任、先进细胞技术公司独立伦理委员会负责人罗纳德•格林(Ronald Green)表示，这一发现“有望在再生医学的进步中起到关键作用”。

　　“它看来是解决美国和其它国家政治僵局的一种途径，”格林教授补充道，“我将它看成布什政府的一次真正机遇，政府可以借此满足人们对胚胎干细胞系的需求，同时又保持其道德立场，即在获取胚胎时不应使其受到破坏。”

　　然而，即使是人为操纵利用哪怕一个胚胎细胞，美国主教团(US Conference of Catholic Bishops)等对胚胎研究持强硬态度的批评者也不太可能接受。他们认为，胚胎细胞在理论上可能成为人。

　　美国总统乔治•W•布什(George W. Bush)上月否决了一项法案。该法案如获通过，将要求联邦政府资助新生成人类胚胎干细胞的试验。欧洲也出现了类似的辩论。在德国等一些国家，用人类胚胎进行研究属违法行为，而在英国等其它国家，政府则资助胚胎研究。

　　先进细胞技术公司的这一突破性成果基于一项单细胞活组织检查。人们将这种检查称为“胚胎植入前基因诊断”(PGD)，受精临床上用其检测试管受精(IVF)胚胎中的基因缺陷。先进细胞技术公司的研究主管罗伯特•兰萨(Robert Lanza)表示，该公司将与一家试管受精临床部门共同完成相关程序，这样一来活组织检查既可用于胚胎植入前基因诊断，也可用于干细胞生成。

[大白呼]

作者: 东莞庄

我的已经牺牲在里面了，现在跑意义不大了。
看了一下历史曲线，有两次都是一个大阳线，然后长期阴跌。
估计这回是死翘翘了。

same feeling

[大白呼]

现在的
risk: reward is a good bet.

[大白呼]

作者: ljw649

3000@1.02 ,拼了！ 穷

Good.

[大白呼]

http://xml.10kwizard.com/filing_raw....&ipage=4355693

FORM 8-K


.......

ITEM 1.01 Entry into a Material Definitive Agreement.

1. Sale of Additional Convertible Debentures and Warrants.

On August 23, 2006, the Company received notices from substantially all of the holders of the Company’s Amortizing Convertible Debentures and Common Stock Purchase Warrants issued under the Securities Purchase Agreement dated as of September 15, 2005 between the Company and the holders of such instruments (the “Securities Purchase Agreement”) indicating that the holders providing the notice (the “Subsequent Purchasers”) have exercised their additional investment option under Section 4.18 of the Securities Purchase Agreement. The Subsequent Purchasers will purchase additional amortizing convertible debentures and warrants to purchase shares of the Company’s common stock for an aggregate purchase price of approximately $8,500,000. Management expects the transaction to close on or about September 7, 2006.

The terms and conditions of the additional debentures and warrants will be identical to those set forth in the original debentures and warrants issued under the Securities Purchase Agreement; provided, however, that (i) the conversion price of the additional debentures will be equal to the lesser of (A) the current conversion price of the debentures issued at the initial closing and (B) the lesser of (1) the average of the five closing prices of the Company’s common stock immediately prior to the notice of exercise of the additional investment and (2) $2.50, and (ii) the exercise price of the additional warrants will be equal to the lesser of (A) the current exercise price of the warrants issued at the initial closing and (B) 110% of the lesser of (1) the average of the five closing prices of the Company’s common stock immediately prior to the notice of exercise of the additional investment and (2) $2.50.

In connection with the purchase, the Company expects to enter into a securities purchase agreement, registration rights agreement and related documents substantially identical to those agreements and other documents executed and delivered in connection with the original investment in September 2005.

Pursuant to the terms of the additional investment option, the Company will be required to file, within 20 days after the closing of the sale of the additional debentures and warrants, a registration statement with the Securities and Exchange Commission registering on behalf of the Subsequent Purchasers the resale of the shares of common stock issuable upon conversion of the additional debentures and the exercise of the additional warrants.

The Securities Purchase Agreement, the registration rights agreement entered into in connection therewith, and the debentures and warrants purchased at the initial closing are described more fully in Section 1 of Item 1.01 of the Company’s Current Report on Form 8-K filed on September 19, 2005, which description is incorporated herein by reference. The complete text of the additional investment option is set forth in Section 4.18 of the Securities Purchase Agreement which is included as an exhibit to that filing.

2. Repricing of Common Stock Purchase Warrants.

On August 24, 2006, the Company agreed to reduce the exercise price of its outstanding warrants to purchase shares of its common stock issued September 15, 2005 (the “Existing Warrants”) from the original exercise price of $2.53 per share to $0.95 for a period beginning at 8:30 a.m. EST on August 25, 2006, and continuing until 5:00 p.m. EST on August 28, 2006 (the “Repricing Term”), provided that a minimum of 85% of the holders of the Existing Warrants exercise the Existing Warrants as repriced. Upon expiration of the Repricing Term, the exercise price of the Existing Warrants will immediately be restored to $2.53 per share. The Company anticipates the receipt of approximately $5,000,000 from the exercise of the Existing Warrants.

On August 24, 2006, the Company agreed to reduce the exercise price of its outstanding $1.27 warrants to purchase shares of its common stock (the “$1.27 Warrants”) from the original exercise price of $1.27 to $0.95 for a period of one year (the “$1.27 Warrants Repricing Term”), provided that a minimum of 85% of the holders of the Existing Warrants exercise the Existing Warrants as repriced. Upon expiration of the $1.27 Warrants Repricing Term, the exercise price of the $1.27 Warrants will immediately be restored to $1.27 per share. The shares underlying the $1.27 Warrants are not subject to a current registration statement.

2



--------------------------------------------------------------------------------





In connection with the repricing, the Company has agreed to issue replacement warrants to all holders exercising their repriced warrants within the repricing periods described above (“Replacement Warrants”). The Replacement Warrants will be identical to the exercised warrants, except that the Replacement Warrants will have an exercise price of $1.60 per share. The Replacement Warrants issued to holders of Existing Warrants will be included in the Company’s registration statement required to be filed with respect to the exercise of the additional investment option described in Item 1.01(1) above. The Company will exercise reasonable efforts to include the Replacement Warrants issued to the holders of $1.27 Warrants in its next filed registration statement.

As a condition to participating in the repricing, each holder exercising repriced warrants agrees that the repricing of the Existing Warrants and $1.27 Warrants and the issuance of the Replacement Warrants will not trigger the antidilution provisions of the Existing Warrants or of the Company’s amortizing convertible debentures.

3. Termination of Senior Secured Convertible Note and Warrant Financing.

The Company has terminated the proposed private placement financing previously announced in its Current Report on Form 8-K filed on August 22, 2006, in accordance with Rule 135c of the Securities Act. The proceeds from the transactions described herein are expected to be sufficient to satisfy the Company’s present capital requirements.

ITEM 9.01 Financial Statements and Exhibits.

(c) EXHIBITS

99.1 Press Release issued by Company on August 25, 2006.

3


...................